| 摘要 |
<p>This invention describes the use of HMGB1 or immunogenic fragments thereof for the active immunoprophylaxis and treatment of systemic inflammatory conditions, such as sepsis, endotoxic shock, hemorrhagic shock and other related syndromes. The administration of HMGB1 or of peptides derived therefrom induces an immune response which is characterized by the generation of anti-HMGB1 antibodies capable of neutralizing the activity of the circulating HMGB1 by inhibiting its ability to promote the secretion of the pro-inflammatory cytokine TNF-a. The efficacy of the prophylactic treatment can be measured by a method which measures the neutralizing activity of the antibodies against the biological effect of HMGB1 on human monocytes.</p> |
